Biognosys this week named Patrick Plewman as its new CEO, taking over from Oliver Rinner, who is now the company's chief scientific officer.
Plewman was previously CEO of cardiovascular diagnostics firm diaDexus. Prior to that he worked at SmithKline Beecham.
The company also announced that it closed an intermediate funding round that will allow it to expand its business in the US and Europe.
Sialix announced this week that is has formed both its scientific advisory board and business advisory board.
The members of the scientific advisory board are: Galit Alter, assistant professor, Harvard Medical School; Robert Anthony, assistant professor, Harvard Medical School; Brian Collins, senior scientist, Momenta Pharmaceuticals; Nicholas Haining, assistant professor, Harvard Medical School; Ganesh Kaundinya, co-founder and chief scientific officer, Momenta Pharmaceuticals; Shiv Pillai, professor, Harvard Medical School; Sean Stevens, vice president of research, Ablexis; Ajit Varki, distinguished professor, University of California, San Diego; Todd Zion, former CEO of SmartCells.
The members of the business advisory board are: Ed Cannon, CEO, Unigen; John Ripple, owner, Ripple Biotech; Roger Swanhey, senior vice president, Novartis International; Todd Zion, former CEO of SmartCells
Conrad Mir has joined Pressure BioSciences as chief financial officer.
Mir has two decades of experience in investment banking, financial restructuring, and corporate reengineering, and he has held executive management roles and served on the boards of directors at several biotech companies, including serving as chairman and CEO of Genetic Immunity and as executive director of Advaxis.